Dr. Joshua Bilenker has served as a member of our board of directors since 2011. Josh is Chief Executive Officer of Loxo Oncology, a biotechnology company focused on cancer therapeutics. He is also a partner at Aisling Capital, a position he has held since 2006. Prior to Aisling Capital, Josh was a Medical Officer in the Office of Oncology Drug Products at the FDA from 2004 to 2006. Josh received his M.D. from The Johns Hopkins School of Medicine and his B.A. from Princeton.